Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies.

Salih HR, Schmetzer HM, Burke C, Starling GC, Dunn R, Pelka-Fleischer R, Nuessler V, Kiener PA.

J Immunol. 2001 Oct 1;167(7):4059-66.

2.

Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.

Salih HR, Kosowski SG, Haluska VF, Starling GC, Loo DT, Lee F, Aruffo AA, Trail PA, Kiener PA.

J Immunol. 2000 Sep 1;165(5):2903-10.

3.
4.

Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.

Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, Okumura K.

Int Immunol. 2002 Mar;14(3):275-86.

6.

Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB.

Loo DT, Chalupny NJ, Bajorath J, Shuford WW, Mittler RS, Aruffo A.

J Biol Chem. 1997 Mar 7;272(10):6448-56.

7.

Costimulation of CD28- T lymphocytes by 4-1BB ligand.

DeBenedette MA, Shahinian A, Mak TW, Watts TH.

J Immunol. 1997 Jan 15;158(2):551-9.

PMID:
8992967
8.

Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis.

Liu GZ, Gomes AC, Putheti P, Karrenbauer V, Kostulas K, Press R, Hillert J, Hjelmström P, Gao XG.

Scand J Immunol. 2006 Oct;64(4):412-9.

9.

A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.

Yoshida H, Katayose Y, Unno M, Suzuki M, Kodama H, Takemura S, Asano R, Hayashi H, Yamamoto K, Matsuno S, Kudo T.

Cancer Immunol Immunother. 2003 Feb;52(2):97-106.

PMID:
12594573
10.
11.

Role of 4-1BB:4-1BB ligand in cancer immunotherapy.

Cheuk AT, Mufti GJ, Guinn BA.

Cancer Gene Ther. 2004 Mar;11(3):215-26. Review.

PMID:
14671675
12.

Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.

Rabu C, Quéméner A, Jacques Y, Echasserieau K, Vusio P, Lang F.

J Biol Chem. 2005 Dec 16;280(50):41472-81.

13.

Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis.

Saito K, Ohara N, Hotokezaka H, Fukumoto S, Yuasa K, Naito M, Fujiwara T, Nakayama K.

J Biol Chem. 2004 Apr 2;279(14):13555-63.

14.

Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28.

Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS.

J Immunol. 1995 Oct 1;155(7):3360-7.

PMID:
7561030
15.

Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.

Cho HR, Kwon B, Yagita H, La S, Lee EA, Kim JE, Akiba H, Kim J, Suh JH, Vinay DS, Ju SA, Kim BS, Mittler RS, Okumura K, Kwon BS.

Transpl Int. 2004 Aug;17(7):351-61.

16.

Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.

Mittler RS, Foell J, McCausland M, Strahotin S, Niu L, Bapat A, Hewes LB.

Immunol Res. 2004;29(1-3):197-208. Review.

PMID:
15181282
17.

Role of 4-1BB in immune responses.

Vinay DS, Kwon BS.

Semin Immunol. 1998 Dec;10(6):481-9. Review.

PMID:
9826581
18.

Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes.

Nam KO, Kang H, Shin SM, Cho KH, Kwon B, Kwon BS, Kim SJ, Lee HW.

J Immunol. 2005 Feb 15;174(4):1898-905.

19.

Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses.

Tan JT, Ha J, Cho HR, Tucker-Burden C, Hendrix RC, Mittler RS, Pearson TC, Larsen CP.

Transplantation. 2000 Jul 15;70(1):175-83.

PMID:
10919597
Items per page

Supplemental Content

Support Center